FDA okays Nabriva’s novel antibiotic Xenleta for pneumoniaIreland-headquartered biotech Nabriva has picked up its first product approval, getting an FDA okay for antibiotic Xenleta as Share XFDA okays Nabriva’s novel antibiotic Xenleta for pneumoniahttps://pharmaphorum.com/news/fda-okays-nabrivas-novel-antibiotic-xenleta-for-pneumonia/
AZ’s Farxiga first in class to improve outcomes in heart failureAstraZeneca has scored a major trial victory after its Farxiga (dapagliflozin) became the first drug in its class Share XAZ’s Farxiga first in class to improve outcomes in heart failurehttps://pharmaphorum.com/news/azs-farxiga-first-in-class-to-improve-outcomes-in-heart-failure/
Fallout over Zolgensma data scandal continues for NovartisNovartis’ troubles over the Zolgensma data manipulation incident show no sign of lessening. The company is on the Share XFallout over Zolgensma data scandal continues for Novartishttps://pharmaphorum.com/news/fallout-over-zolgensma-data-scandal-continues-for-novartis/
Pharming buys rare disease drug from Novartis for $20mPharming has bought a late-stage pipeline drug aimed at a rare disease of the immune system from Novartis Share XPharming buys rare disease drug from Novartis for $20mhttps://pharmaphorum.com/news/pharming-buys-rare-disease-drug-from-novartis-for-20m/
First effective Ebola treatment a step closer after breakthrough trialClinical trials of four experimental treatments for Ebola in the Congo have been halted early after two of Share XFirst effective Ebola treatment a step closer after breakthrough trialhttps://pharmaphorum.com/news/ebola-virus-clinical-trial-breakthrough/
US senators blast Novartis for Zolgensma data falsificationUS politicians have urged the FDA to come down hard on Novartis for failing to disclose manipulated data Share XUS senators blast Novartis for Zolgensma data falsificationhttps://pharmaphorum.com/news/us-senators-blast-novartis-for-zolgensma-data-falsification/
Science sector lauds UK’s visa scheme, but repeats no-deal Brexit warningBoris Johnson has ordered a new fast-track visa scheme to make it easier for top scientists to work Share XScience sector lauds UK’s visa scheme, but repeats no-deal Brexit warninghttps://pharmaphorum.com/news/science-sector-lauds-uks-visa-scheme-but-repeats-no-deal-brexit-warning/
Bayer boosts cell therapy pipeline with BlueRock acquisitionBayer has announced it is fully acquiring US cell therapy biotech BlueRock Therapeutics, whose cell therapy pipeline includes Share XBayer boosts cell therapy pipeline with BlueRock acquisitionhttps://pharmaphorum.com/news/bayer-boosts-cell-therapy-pipeline-with-bluerock-acquisition/
Rhythm doesn’t miss a beat as obesity drug clears phase 3 testRhythm Pharma says it has reported positive results for its obesity drug setmelanotide in two phase 3 trials, Share XRhythm doesn’t miss a beat as obesity drug clears phase 3 testhttps://pharmaphorum.com/news/rhythm-doesnt-miss-a-beat-as-obesity-drug-clears-phase-3-test/
Astellas pushes non-hormonal menopause drug into phase 3Japan’s Astellas has started treating patients in a phase 3 trial of fezolinetant, a non-hormonal drug for menopausal Share XAstellas pushes non-hormonal menopause drug into phase 3https://pharmaphorum.com/news/astellas-pushes-non-hormonal-menopause-drug-into-phase-3/
AZ/MSD’s Lynparza sees positive results in prostate cancerAstraZeneca and MSD have announced positive phase III results for their PARP inhibitor Lynparza (olaparib) in metastatic castration-resistant Share XAZ/MSD’s Lynparza sees positive results in prostate cancerhttps://pharmaphorum.com/news/az-msds-lynparza-sees-positive-results-in-prostate-cancer/
GSK exits Ebola vaccine R&D as J&J rival starts Uganda trialGlaxoSmithKline has licensed vaccines for Ebola to the US Sabin Vaccine Institute, just as a major trial of Share XGSK exits Ebola vaccine R&D as J&J rival starts Uganda trialhttps://pharmaphorum.com/news/gsk-exits-ebola-vaccine-rd-as-jj-rival-starts-uganda-trial/
Lilly firms up case for Emgality in migraine market chaseEli Lilly’s third-to-market migraine prevention drug Emgality has a lot of ground to make up on its rivals, Share XLilly firms up case for Emgality in migraine market chasehttps://pharmaphorum.com/news/lilly-firms-up-case-for-emgality-in-migraine-market-chase/
Roche scores with Tecentriq combo in first-line bladder cancerRoche’s Tecentriq has become the first checkpoint inhibitor to show a benefit in previously-untreated patients with bladder cancer Share XRoche scores with Tecentriq combo in first-line bladder cancerhttps://pharmaphorum.com/news/roche-scores-with-tecentriq-combo-in-first-line-bladder-cancer/
Sosei Heptares bags another big partnership, this time with TakedaJapanese biotech Sosei’s buyout of the UK’s Heptares four years ago has rewarded it with a string of Share XSosei Heptares bags another big partnership, this time with Takedahttps://pharmaphorum.com/news/sosei-heptares-bags-another-big-partnership-this-time-with-takeda/
Could Kyowa Kirin be eyeing ophthalmology use for cancer drug tivozanib?Kyowa Kirin has bought back rights outside of cancer to tivozanib, amending an agreement dating back to 2006 Share XCould Kyowa Kirin be eyeing ophthalmology use for cancer drug tivozanib?https://pharmaphorum.com/news/could-kyowa-kirin-be-eyeing-ophthalmology-use-for-cancer-drug-tivozanib/
Alzheimer’s blood test could boost research after successive trial failuresA blood test could be used to diagnose Alzheimer’s before symptoms arise, providing an alternative to expensive brain Share XAlzheimer’s blood test could boost research after successive trial failureshttps://pharmaphorum.com/news/alzheimers-blood-test-could-boost-research-after-successive-trial-failures/
Novo extends R&D alliance with AI specialist e-TherapeuticsNovo Nordisk must have liked what it saw in the first few months of its R&D tie-up with Share XNovo extends R&D alliance with AI specialist e-Therapeuticshttps://pharmaphorum.com/news/novo-extends-rd-alliance-with-ai-specialist-e-therapeutics/
